Evidence map›Paper›PMID 31558677›Full record

ArticleHaematologica2020

Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study.

Francesco Paciullo, Loredana Bury, Patrizia Noris, Emanuela Falcinelli, Federica Melazzini, Sara Orsini, Carlo Zaninetti, Rezan Abdul-Kadir, Deborah Obeng-Tuudah, Paula G Heller and 22 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice.Haemophilia : the official journal of the World Federation of Hemophilia · 2025
    Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Observational
  9. Article
  10. Platelet-Neutrophil Crosstalk in Thrombosis.International journal of molecular sciences · 2023
    Review
  11. Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 12 countries.

Francesco PaciulloDepartment of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
Loredana BuryDepartment of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
Patrizia NorisDepartment of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
Emanuela FalcinelliDepartment of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
Federica MelazziniDepartment of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
Sara OrsiniDepartment of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.
Carlo ZaninettiDepartment of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
Rezan Abdul-KadirHaemophilia Centre and Haemostasis Unit, The Royal Free Foundation Hospital and University College London, London, UK.
Deborah Obeng-TuudahHaemophilia Centre and Haemostasis Unit, The Royal Free Foundation Hospital and University College London, London, UK.
Paula G HellerHematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina.
Ana C GlembotskyHematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina.
Fabrizio FabrisClinica Medica 1 - Medicina Interna CLOPD, Dipartimento Assistenziale Integrato di Medicina, Azienda-Ospedale Università di Padova, Dipartimento di Medicina, Università di Padova, Padova, Italy.
Jose RiveraServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
Maria Luisa LozanoServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
Nora ButtaUnidad de Hematología, Hospital Universitario La Paz-IDIPaz, Madrid, Spain.
Remi FavierAssistance Publique-Hôpitaux de Paris, Armand Trousseau Children's Hospital, French Reference Centre for Inherited Platelet Disorders, Paris, France.
Ana Rosa CidUnidad de Hemostasia y Trombosis, Hospital Universitario y Politecnico La Fe, Valencia, Spain.
Marc FouassierConsultations d'Hémostase - CRTH, CHU de Nantes, Nantes, France.
Gian Marco PoddaMedicina III, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.
Cristina SantoroHematology, Department of Translational and Precision Medicine, La Sapienza University of Rome, Rome, Italy.
Elvira GrandoneUnità di Ricerca in Aterosclerosi e Trombosi, I.R.C.C.S. "Casa Sollievo della Sofferenza", S. Giovanni Rotondo, Foggia, Italy.
Yvonne HenskensHematological Laboratory, Maastricht University Medical Centre, Maastricht, the Netherlands.
Paquita NurdenServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
Barbara ZiegerDivision of Pediatric Hematology and Oncology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany.
Adam CukerPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Katrien DevreeseCoagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Alberto TosettoHematology Department, S. Bortolo Hospital, Vicenza, Italy.
Erica De CandiaHemostasis and Thrombosis Unit, Insitute of Internal Medicine, Policlinico Agostino Gemelli Foundation, IRCCS, Rome, Italy.
Arnaud DupuisUniversité de Strasbourg, Institut National de la Santé et de la Recherche Médicale, Etablissement Français du Sang Grand Est, Unité Mixte de Recherche-S 1255, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France.
Koji MiyazakiDepartment of Transfusion and Cell Transplantation Kitasato University School of Medicine, Sagamihara, Japan.
Maha OthmanDepartment of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada.
Paolo GreseleDepartment of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy paolo.gresele@unipg.it.
University of Perugia · ITCentro Regional de Hemodonación · ESUniversity of Pavia · ITConsejo Nacional de Investigaciones Científicas y Técnicas · ARRoyal Free London NHS Foundation Trust · GBCentre Hospitalier Universitaire de Nantes · FRÉtablissement Français du Sang · FRGhent University Hospital · BEHôpital Armand-Trousseau · FRHospital Universitario La Paz · ESKitasato University · JPMaastricht University Medical Centre · NLOspedale San Bortolo · ITQueen's University · CASapienza University of Rome · ITSechenov University · RUSociedad Española de Trombosis y Hemostasia · ESUniversità Cattolica del Sacro Cuore · ITUniversity of Freiburg · DEUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major surgery is associated with an increased risk of venous thromboembolism (VTE), thus the application of mechanical or pharmacologic prophylaxis is recommended. The incidence of VTE in patients with inherited platelet disorders (IPD) undergoing surgical procedures is unknown and no information on the current use and safety of thromboprophylaxis, particularly of low-molecular-weight-heparin in these patients is available. Here we explored the approach to thromboprophylaxis and thrombotic outcomes in IPD patients undergoing surgery at VTE-risk participating in the multicenter SPATA study. We evaluated 210 surgical procedures carried out in 155 patients with well-defined forms of IPD (VTE-risk: 31% high, 28.6% intermediate, 25.2% low, 15.2% very low). The use of thromboprophylaxis was low (23.3% of procedures), with higher prevalence in orthopedic and gynecological surgeries, and was related to VTE-risk. The most frequently employed thromboprophylaxis was mechanical and appeared to be effective, as no patients developed thrombosis, including patients belonging to the highest VTE-risk classes. Low-molecular-weight-heparin use was low (10.5%) and it did not influence the incidence of post-surgical bleeding or of antihemorrhagic prohemostatic interventions use. Two thromboembolic events were registered, both occurring after high VTE-risk procedures in patients who did not receive thromboprophylaxis (4.7%). Our findings suggest that VTE incidence is low in patients with IPD undergoing surgery at VTE-risk and that it is predicted by the Caprini score. Mechanical thromboprophylaxis may be of benefit in patients with IPD undergoing invasive procedures at VTE-risk and low-molecular-weight-heparin should be considered for major surgery.

Indexed as

ThrombosisVenous ThromboembolismAnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-WeightHumansPostoperative ComplicationsAnticoagulantsFibrinolytic AgentsHeparin, Low-Molecular-Weight

Identifiers

PMID31558677
PMCPMC7327644
OpenAlexW2974951843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.